Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 14 studies | 40% ± 16% | |
respiratory goblet cell | 5 studies | 32% ± 8% | |
basal cell | 4 studies | 36% ± 18% | |
club cell | 4 studies | 25% ± 3% | |
deuterosomal cell | 4 studies | 31% ± 12% | |
mesothelial cell | 4 studies | 35% ± 7% | |
secretory cell | 3 studies | 42% ± 18% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 25% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 79% | 730.53 | 454 / 578 | 54% | 14.54 | 621 / 1155 |
intestine | 74% | 136.28 | 718 / 966 | 42% | 1.69 | 221 / 527 |
bladder | 52% | 30.86 | 11 / 21 | 60% | 4.49 | 301 / 504 |
prostate | 19% | 9.19 | 47 / 245 | 62% | 7.85 | 311 / 502 |
breast | 32% | 74.16 | 148 / 459 | 44% | 3.19 | 493 / 1118 |
skin | 55% | 49.95 | 996 / 1809 | 11% | 1.62 | 50 / 472 |
esophagus | 18% | 53.66 | 264 / 1445 | 33% | 3.54 | 61 / 183 |
uterus | 7% | 10.39 | 12 / 170 | 43% | 15.00 | 197 / 459 |
brain | 45% | 43.48 | 1196 / 2642 | 3% | 0.45 | 24 / 705 |
lymph node | 0% | 0 | 0 / 0 | 48% | 2.19 | 14 / 29 |
stomach | 7% | 16.07 | 26 / 359 | 34% | 1.42 | 97 / 286 |
adipose | 40% | 2209.96 | 485 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 40% | 160.43 | 372 / 929 | 0% | 0 | 0 / 0 |
heart | 35% | 163.45 | 302 / 861 | 0% | 0 | 0 / 0 |
ovary | 20% | 11.65 | 36 / 180 | 12% | 0.44 | 53 / 430 |
spleen | 28% | 16.28 | 67 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 20% | 4.02 | 9 / 45 |
pancreas | 0% | 0.60 | 1 / 328 | 11% | 0.42 | 19 / 178 |
thymus | 2% | 1.98 | 16 / 653 | 5% | 0.14 | 29 / 605 |
blood vessel | 7% | 14.86 | 87 / 1335 | 0% | 0 | 0 / 0 |
liver | 1% | 0.47 | 2 / 226 | 4% | 0.13 | 17 / 406 |
muscle | 3% | 1.52 | 27 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 1% | 0.54 | 2 / 258 | 0% | 0.06 | 1 / 230 |
kidney | 0% | 0 | 0 / 89 | 1% | 0.03 | 6 / 901 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030838 | Biological process | positive regulation of actin filament polymerization |
GO_0006954 | Biological process | inflammatory response |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_2001303 | Biological process | lipoxin A4 biosynthetic process |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0034440 | Biological process | lipid oxidation |
GO_0010811 | Biological process | positive regulation of cell-substrate adhesion |
GO_0019395 | Biological process | fatty acid oxidation |
GO_0019372 | Biological process | lipoxygenase pathway |
GO_0002820 | Biological process | negative regulation of adaptive immune response |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0035358 | Biological process | regulation of peroxisome proliferator activated receptor signaling pathway |
GO_1901074 | Biological process | regulation of engulfment of apoptotic cell |
GO_0071277 | Biological process | cellular response to calcium ion |
GO_0042060 | Biological process | wound healing |
GO_0043277 | Biological process | apoptotic cell clearance |
GO_0035963 | Biological process | cellular response to interleukin-13 |
GO_0030282 | Biological process | bone mineralization |
GO_0042759 | Biological process | long-chain fatty acid biosynthetic process |
GO_0001503 | Biological process | ossification |
GO_0006629 | Biological process | lipid metabolic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0051122 | Biological process | hepoxilin biosynthetic process |
GO_0006646 | Biological process | phosphatidylethanolamine biosynthetic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005811 | Cellular component | lipid droplet |
GO_0016020 | Cellular component | membrane |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0005829 | Cellular component | cytosol |
GO_0050473 | Molecular function | arachidonate 15-lipoxygenase activity |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0005506 | Molecular function | iron ion binding |
GO_0004052 | Molecular function | arachidonate 12(S)-lipoxygenase activity |
GO_0016165 | Molecular function | linoleate 13S-lipoxygenase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ALOX15 |
Protein name | Polyunsaturated fatty acid lipoxygenase ALOX15 (12/15-lipoxygenase) (Arachidonate 12-lipoxygenase, leukocyte-type) (12-LOX) (EC 1.13.11.31) (Arachidonate 15-lipoxygenase) (15-LOX) (15-LOX-1) (EC 1.13.11.33) (Arachidonate omega-6 lipoxygenase) (Hepoxilin A3 synthase Alox15) (EC 1.13.11.-) (Linoleate 13S-lipoxygenase) (EC 1.13.11.12) |
Synonyms | LOG15 |
Description | FUNCTION: Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators . It inserts peroxyl groups at C12 or C15 of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) producing both 12-hydroperoxyeicosatetraenoate/12-HPETE and 15-hydroperoxyeicosatetraenoate/15-HPETE . It may then act on 12-HPETE to produce hepoxilins, which may show pro-inflammatory properties (By similarity). Can also peroxidize linoleate ((9Z,12Z)-octadecadienoate) to 13-hydroperoxyoctadecadienoate/13-HPODE . May participate in the sequential oxidations of DHA ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro-resolving mediators (SPMs)like resolvin D5 ((7S,17S)-diHPDHA) and (7S,14S)-diHPDHA, that actively down-regulate the immune response and have anti-aggregation properties with platelets . Can convert epoxy fatty acids to hydroperoxy-epoxides derivatives followed by an intramolecular nucleophilic substitution leading to the formation of monocyclic endoperoxides . Plays an important role during the maintenance of self-tolerance by peroxidizing membrane-bound phosphatidylethanolamine which can then signal the sorting process for clearance of apoptotic cells during inflammation and prevent an autoimmune response. In addition to its role in the immune and inflammatory responses, this enzyme may play a role in epithelial wound healing in the cornea through production of lipoxin A4 (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1; 10R,17S-HDHA), both lipid autacoids exhibit anti-inflammatory and neuroprotective properties. Furthermore, it may regulate actin polymerization which is crucial for several biological processes such as the phagocytosis of apoptotic cells. It is also implicated in the generation of endogenous ligands for peroxisome proliferator activated receptor (PPAR-gamma), hence modulating macrophage development and function. It may also exert a negative effect on skeletal development by regulating bone mass through this pathway. As well as participates in ER stress and downstream inflammation in adipocytes, pancreatic islets, and liver (By similarity). Finally, it is also involved in the cellular response to IL13/interleukin-13 . . |
Accessions | ENST00000570836.6 [P16050-1] ENST00000574640.1 [P16050-2] ENST00000293761.8 [P16050-1] P16050 |